A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data

References

• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.29, iv192–iv237 (2018).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ^†Updated version published 15 September 2020 by the ESMO Guidelines Committee.The ESMO Clinical Practice Guidelines on metastatic non-small cell lung cancer (NSCLC). www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer (Accessed 18May2022).
   Google Scholar
• Wu S-G , ShihJ-Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Molecular Cancer.17, 38 (2018).
   PubMed Web of Science ®Google Scholar
• Wu SG , LiuYN, TsaiMFet al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget.7, 12404–12413 (2016).
   PubMed Web of Science ®Google Scholar
• Cross DA , AshtonSE, GhiorghiuSet al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov.4, 1046–1061 (2014).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, AhnMJet al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med.376, 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N. Engl. J. Med.378, 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T , NakagawaK, ChoBCet al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol.36, 3290–3297 (2018).
   Web of Science ®Google Scholar
• Wu YL , AhnMJ, GarassinoMCet al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small cell lung cancer: data from a randomized phase III trial (AURA3). J. Clin. Oncol.36, 2702–2709 (2018).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. TAGRISSO® (osimertinib) . Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf (Accessed 18May2022).
   Google Scholar
• European Medicines Agency . TAGRISSO (osimertinib). Product information. www.ema.europa.eu/en/documents/overview/tagrisso-epar-medicine-overview_en.pdf (Accessed 18May2022).
   Google Scholar
• Papadimitrakopoulou VA , MokTS, HanJYet al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann. Oncol.31, 1536–1544 (2020).
   PubMed Web of Science ®Google Scholar
• Mainis F , WuYL, de CastroGJret al. ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncol.15, 3003–3014 (2019).
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration . Real-world evidence. www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (Accessed 18May2022).
   Google Scholar
• Ahn MJ , TsaiCM, ShepherdFAet al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer.125, 892–901 (2019).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , VansteenkisteJ, PlanchardDet al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med.382, 41–50 (2019).
   PubMed Web of Science ®Google Scholar
• Ahn MJ , ChiuCH, ChengYet al. Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J. Thorac. Oncol.15, 637–648 (2020).
   PubMed Web of Science ®Google Scholar
• Yang JCH , KimSW, KimDWet al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J. Clin. Oncol.38, 538–547 (2020).
   PubMed Web of Science ®Google Scholar
• Wang X , CaiJ, ZengZet al. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study. BMC Cancer21, 873 (2021).
   PubMed Web of Science ®Google Scholar
• Sharma M , NathanyS, NarayanSet al. Real-world data of osimertinib in the management of leptomeningeal metastases in EGFR mutant NSCLC: light at the end of the tunnel? J. Clin. Oncol. 39, e21197–e21197 (2021).
   Web of Science ®Google Scholar
• Colclough N , ChenK, JohnströmPet al. Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs. Clin. Cancer Res.27, 189–201 (2021).
   PubMed Web of Science ®Google Scholar
• Nadler E , EspiritoJL, PavilackMet al. Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer. Future Oncol.16, 1575–1584 (2020).
   PubMed Web of Science ®Google Scholar
• Wang C , ZhaoK, HuSet al. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: a pooled analysis of 438 patients. Lung Cancer172, 86–93 (2022).
   PubMed Web of Science ®Google Scholar
• Yang S , MaoS, LiXet al. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Lung Cancer139, 133–139 (2020).
   PubMed Web of Science ®Google Scholar
• Guo K , ZhangZ, HanLet al. Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Onco. Targets Ther.8, 3289–3296 (2015).
   PubMed Web of Science ®Google Scholar
• Cho JH , LimSH, AnHJet al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J. Clin. Oncol.38, 488–495 (2020).
   PubMed Web of Science ®Google Scholar
• Masood A , KanchaRK, SubramanianJ. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: focus on afatinib. Semin. Oncol.46, 271–283 (2019).
   PubMed Web of Science ®Google Scholar
• Hanna NH , RobinsonAG, TeminSet al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol.39, 1040–1091 (2021).
   PubMed Web of Science ®Google Scholar
• Wu Y-L , TsuboiM, HeJet al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med.383, 1711–1723 (2020).
   PubMed Web of Science ®Google Scholar
• Nieva J , ReckampK, TaylorAet al. P1.01-96 US real-world management of EGFR-mutated advanced NSCLC: survival after first-line EGFR-tyrosine kinase inhibitor treatment. J. Thorac. Oncol.14, S398–S399 (2019).
   Google Scholar
• Geldof T , HuysI, Van DyckW. Real-world evidence gathering in oncology: the need for a biomedical big data insight-providing federated network. Front Med.8, 43 (2019).
   Google Scholar